Gynecologic Oncology Program


Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun;129(3):486-94.

Eskander RN, Baruah J, Nayak R, Brueseke T, Ji T, Wardeh R, Tewari KS. Outside slide review in gynecologic oncology: impact on patient care and treatment. Int J Gynecol Pathol. 2013 May;32(3):293-8.

Pinn-Bingham M, Puthawala AA, Syed AM, Sharma A, DiSaia P, Berman M, Tewari KS, Randall-Whitis L, et al. Outcomes of high-dose rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results. Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):714-20.

Liao SY, Rodgers WH, Kauderer J, Darcy KM, Carter R, Susumu N, Nagao S, Walker JL, Hatae M, Stanbridge EJ. Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynecologic Oncology Group study. British J. of Cancer 108, 613-620, 2013.

Carter R, Kang L, Darcy KM, Kauderer J, Liao SY, Rodgers WH, Walker JL, Lankes HA, Dunn ST, Stanbridge EJ. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study. Cancer causes Control 23:2013-2021, 2012.

Tewari KS. American Society of Clinical Oncology 2012 Annual Meeting: highlights from the gynecologic oncology track. Int J Gynecol Cancer. 2012 Nov;22(9):1634-9.

Tewari KS. Adavanced cytoreductive surgery workshop report. Int J Gynecol Cancer. 2012 Nov;22(9):1604-10.

Chase DM, Osann K, Sepina N, Wenzel L, Tewari KS. The challenge of follow-up in a low-income colposcopy clinic: characteristics associated with noncompliance in high-risk populations. J Low Genit Tract Dis. 2012 Oct;16(4):345-51.

Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012;4:395-404.

Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2012 Mar; 124(3):563-8.

Tewari KS, Filiaci VL, Spirtos NM, Mannel RS, Thigpen JT, Cibull ML, Monk BJ, Randall ME. Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr;125(1):87-93.

Dellinger TH, Planutis K, Tewari KS, Holcombe RF. Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther. 2012 Jan;12(1):51-62.

Liao SY,Rodgers WH, Kauderen J, Bonfiglio TA, Darcy KM, Carter R, Levine L, Spirtos NM, Susumu N, Fujiwaras K, Walker JL, Hates M, Stanbridge EJ. Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical splasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study. British J. of Cancer 104, 353-360, 2011.

Tewari KS, Monk BJ. American Society of Clinical Oncology 2011 Annual Meeting update: summary of selected gynecologic cancer abstracts. Gynecol Oncol. 2011 Aug;122(2):209-12.

Eskander RN, Randall LM, Berman ML, Tewari KS, DiSaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Aug;205(2):103-10.

Jordan S, Randall LM, Karamurzin Y, Ward P, Lin F, Brewster W, Monk BJ. Differentiating squamous cell carcinoma of the cervix and epithelioid trophoblastic tumor. Int J Gynecol Cancer. 2011 Jul; 21(5):918-22.

Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol. 2011 Mar 14. [Epub ahead of print] PubMed PMID: 21411052.

Moniaga NC, Randall LM. Malignant Mixed Ovarian Germ Cell Tumor with Embryonal Component. J Pediatr Adolesc Gynecol. 2011 Feb;24(1):e1-3.

Eskander RN, Randall LM. Bevacizumab in the treatment of ovarian cancer. Biologics. 2011;5:1-5. Epub 2011 Jan 11.

Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, et al. Randomized phase III trial of Tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group study. Gynecol Oncol. 2010 Dec;119(3):444-50.

Chase DM, Mathur N, Tewari KS. Drug discovery in ovarian cancer. Recent Pat Anticancer Drug Discov. 2010 Nov;5(3):251-60.

Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, et al. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct;20(7):1137-41.

Han ES, Burger RA, Darcy KM, Sill MW,Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010 Sep 24. [Epub ahead of print] PMID: 20870280.

Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA. Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group Study. Gynecol Oncol. 2010 Sep 14. [Epub ahead of print] PMID: 20846714.

Randall LM,Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol. 2010 Jun;117(3):497-504. Review. PMID: 20363017.

Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol. 2010 Feb;8(2):108-15.

Kalantari M, Chase DM, Tewari KS, Bernard HU. Recombination of human papillovavirus-16 and host DNA in exfoliated cervical cells: a pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol. 2010 Feb;82(2):311-20.

Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. . Gynecol Oncol. 2009 Mar;112(3):583-9.

Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbidge EJ. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov 12. 116, 452-458, 2010.